# Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

> **NCT00024154** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 132 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** gefitinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00024154
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024154, "Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00024154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*